8.22  0.06 (0.74%)		03-02 16:00
Open: 8.085 High: 8.5 Volume: 556,326		Pre. Close: 8.16 Low: 7.91 Market Cap: 216(M)

Short term
Mid term
Targets	6-month :	9.92	1-year :	11.59
Resists	First :	8.5	Second :	9.92
Pivot price	6.47
Supports	First :	5.94	Second :	4.36
MAs	MA(5) :	7.86	MA(20) :	6.55
	MA(100) :	8.2	MA(250) :	8.01
MACD	MACD :	0.2	Signal :	-0.1
%K %D	K(14,3) :	95.7	D(3) :	96.1
RSI	RSI(14): 65.8
52-week	High :	13.34	Low :	4.29

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ CVRX ] has closed below upper band by 12.9%. Bollinger Bands are 99.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	8.51 - 8.53	8.53 - 8.56
Low:	7.84 - 7.87	7.87 - 7.9
Close:	8.17 - 8.21	8.21 - 8.26

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Mon, 02 Mar 2026
CVRx Announces Late-Breaking Data and Scientific - GlobeNewswire

Mon, 02 Mar 2026
Heart failure device Barostim tested in 400 patients, data due at THT 2026 - Stock Titan

Sat, 28 Feb 2026
SGP,CVRX Short Interest - Finviz

Fri, 27 Feb 2026
IMA,CVRX Revenue Breakdown - Finviz

Thu, 19 Feb 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX - PR Newswire

Sun, 15 Feb 2026
Analysts Are Updating Their CVRx, Inc. (NASDAQ:CVRX) Estimates After Its Full-Year Results - simplywall.st

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Devices
Shares Out	26 (M)
Shares Float	17 (M)
Held by Insiders	4.2 (%)
Held by Institutions	69.8 (%)
Shares Short	1,640 (K)
Shares Short P.Month	1,340 (K)

EPS	-2.04
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1.5
Profit Margin	-94.1 %
Operating Margin	-69.9 %
Return on Assets (ttm)	-26.9 %
Return on Equity (ttm)	-96.6 %
Qtrly Rev. Growth	4.4 %
Gross Profit (p.s.)	1.83
Sales Per Share	2.15
EBITDA (p.s.)	-1.92
Qtrly Earnings Growth	0 %
Operating Cash Flow	-40 (M)
Levered Free Cash Flow	-24 (M)

PE Ratio	-4.03
PEG Ratio	0
Price to Book value	5.48
Price to Sales	3.81
Price to Cash Flow	-5.39

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.